Skip to Main Content

Paper Details

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
PLoS One
2
2022
Author NameAffiliation
Gerhardt AttardUniversity College London Cancer Institute
  • 1 - 1

Datasets

Release 1.2